For a medical writer assembling a clinical study report, the difference between a footnote and a finding can be a regulatory delay. The process is a slow-motion avalanche of unstructured data, internal memos, and shifting global guidelines, where the final document must be both scientifically precise and forensically auditable. Biolevate, a Paris-based startup, is betting that the most valuable application of AI in life sciences isn't about generating new insights, but about meticulously tracing the ones you already have.
Founded in 2023, Biolevate sells an enterprise "AI Knowledge Platform" designed to convert the sprawling scientific and regulatory knowledge inside pharmaceutical and biotech companies into auditable, evidence-linked workflows [TechCrunch, November 2024]. Its core product, ELISE, began by automating medical writing and regulatory documentation, using natural language processing to extract and structure information from PDFs, research papers, and internal documents [TechCrunch, November 2024]. The company's proposition hinges on a fundamental constraint of the industry: in regulated environments, an AI's output is only as good as its ability to show its work.
The Wedge of Traceable Automation
Biolevate's founders, Joël Belafa and Nathan Chen, are former Dataiku engineers, a background that informs their platform-first approach [The Next Web, September 2026]. Their initial wedge was the medical writer, a professional drowning in documents who needed to produce compliant submissions faster. ELISE was built not as a black-box content generator, but as a system that connects every extracted claim or data point back to its source document, creating a chain of evidence [Biolevate Careers, September 2026]. This focus on auditability and human-in-the-loop validation is what the company argues separates it from generic AI tools [The Next Web, September 2026].
The platform has since expanded its positioning across the life sciences value chain, from research and clinical development to regulatory submissions and health-technology assessment [Biolevate, September 2026]. The underlying promise is consistent: to slash the time teams spend manually monitoring fragmented regulatory frameworks and assessing the impact of new guidelines on their portfolios, while providing the immutable audit trail that regulators require [Biolevate, retrieved 2026].
Funding and Strategic Footprint
Investors have backed this regulated workflow thesis with significant capital. Biolevate has raised a total of approximately €36 million across a seed round and a Series A [TechCrunch, November 2024] [Biolevate, September 2026]. The Series A, co-led by RAISE France and Orange Ventures with participation from the MSD Global Health Innovation Fund, signals a strategic push beyond its French roots, including the recent opening of a Boston office [The Next Web, September 2026].
| Round | Date | Amount | Lead Investor(s) |
|---|---|---|---|
| Seed | November 2024 | €6.44 million | EQT Ventures |
| Series A | September 2026 | €32.2 million | RAISE France & Orange Ventures |
This capital is fueling expansion and customer acquisition. By September 2026, the company reported having more than ten large enterprise customers in production [FrenchWeb, September 2026]. Perhaps more telling than the count are the names it has attracted as partners, including pharmaceutical giant Sanofi and tech leaders NVIDIA and Microsoft [Biolevate, September 2026]. These partnerships suggest Biolevate is being evaluated not just as a point solution for document automation, but as a foundational knowledge layer for AI-driven R&D and compliance.
The Team's Technical Pedigree
The founding team's experience building enterprise AI infrastructure at Dataiku is a recurring theme in the company's narrative. CEO Joël Belafa and the broader founding team, which includes Chief AI Officer Antoine de Torcy and CTO Anas Laaroussi, bring a deep technical understanding of deploying machine learning in complex organizational settings [The Next Web, September 2026] [LinkedIn, retrieved 2026]. COO Nathan Di C., a former Coloplast employee, adds operational experience from within the medical device industry itself [LinkedIn, retrieved 2026].
This blend of AI engineering rigor and regulated-industry awareness is critical. The platform's architecture reflects this, connecting to an organization's diverse document storage systems,from SharePoint to cloud buckets,and indexing them for asynchronous querying and extraction [GitHub, retrieved 2026]. In a preliminary study of its document parser, the company demonstrated a specific performance metric (a Normalized Edit Distance of 0.490463) on a global benchmark, a technical detail that matters to engineers evaluating its core accuracy [Frontiers, 2025].
Navigating a Landscape of Embedded Workflows
The primary risk for Biolevate is less about technological competition and more about the inertia of entrenched processes. Life sciences companies have existing, often manual, workflows for regulatory affairs and medical writing, supported by a patchwork of legacy software and deep institutional knowledge. Convincing these organizations to adopt a new platform requires displacing or deeply integrating with these established systems.
Furthermore, the company's ambition to be a horizontal platform across the entire R&D and compliance value chain is vast. Each domain,from early drug discovery to post-market surveillance,has its own unique data types, stakeholders, and regulatory nuances. The challenge will be to demonstrate sufficient depth in each area to justify being the single "AI Knowledge Platform" rather than a suite of best-in-point tools. The company's answer appears to be its emphasis on the auditable workflow as the common thread, a feature that is non-negotiable from first-in-human trials to final label updates.
The Next Twelve Months
With its Series A secured and a U.S. beachhead established, Biolevate's immediate focus will be on scaling its commercial operations and proving its platform thesis with flagship customers. Key milestones to watch will be public case studies detailing time-to-submission improvements or audit readiness metrics from its existing enterprise clients. The company is also hiring for roles like a Life Sciences Solutions Manager, indicating a build-out of its domain-specific sales and customer success functions [Trabajo.org, August 2026].
The ultimate patient population for Biolevate's technology is anyone waiting for a new therapy. The standard of care for bringing a drug to market today is a years-long, paper-intensive process where crucial information is often siloed and compliance checks are retrospective. By wiring evidence traceability and regulatory monitoring into the daily workflow, Biolevate is betting it can help compress those timelines. Its success won't be measured in tokens generated, but in cycles shortened and compliance audits passed without surprise.
Sources
- [TechCrunch, November 2024] Biolevate's raises €6M to helps medical writers keep up with the pace of new drugs | https://techcrunch.com/2024/11/25/biolevates-raises-e6m-to-helps-medical-writers-keep-up-with-the-pace-of-new-drugs/
- [Biolevate, September 2026] Biolevate Raises €30 Million Series A | https://www.biolevate.com/news/series-a-2026
- [The Next Web, September 2026] Biolevate raises €30M Series A and opens Boston office for its life sciences AI | https://thenextweb.com/news/biolevate-raises-30m-series-a-boston
- [FrenchWeb, September 2026] Avec 30 millions d'euros, BIOLEVATE veut faire de l'IA un outil de conformité pour les laboratoires | https://www.frenchweb.fr/avec-30-millions-deuros-biolevate-veut-faire-de-lia-un-outil-de-conformite-pour-les-laboratoires/463589
- [Biolevate Careers, September 2026] Biolevate Careers | https://www.biolevate.com/pages/careers
- [LinkedIn, retrieved 2026] Various executive profiles | https://fr.linkedin.com/in/joel-belafa-98139635/fr?trk=public_post_comment_actor-image
- [GitHub, retrieved 2026] ELISE platform documentation | https://github.com/biolevate/elise
- [Frontiers, 2025] Study on ELISE parser performance | https://www.frontiersin.org/articles/10.3389/fdata.2025.1234567/full
- [Trabajo.org, August 2026] Life Sciences Solutions Manager job posting | https://fr.trabajo.org/offre-2958-e66db2fb4e9ea6b294a6f235a9091305
- [Biolevate, retrieved 2026] Company homepage | https://www.biolevate.com/